Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 4 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 49Neoplasms 36Prostatic Neoplasms 25Carcinoma, Non-Small-Cell Lung 25Polycystic Ovary Syndrome 16Pain 15Keratosis, Actinic 14Leukemia 12Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 10Lung Neoplasms 10Leiomyoma 10Carcinoma, Hepatocellular 10Ovarian Neoplasms 9Neoplasm Metastasis 9Lymphoma, Follicular 9Carcinoma, Renal Cell 9Brain Neoplasms 9Neuroendocrine Tumors 8Arthritis, Rheumatoid 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Kidney Neoplasms 7Head and Neck Neoplasms 7Colonic Neoplasms 7Cancer Pain 7Multiple Myeloma 6Lymphoma 6Liver Neoplasms 6

Interventions

olaparib 1enzalutamide 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Has results × Metastatic Castration-resistant Prostate Cancer × Clear all
NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡